Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer

Abstract

In this article, we focus on a variety of immunosuppression scenarios and whether multikinase inhibitors, as systemic therapy for advanced thyroid carcinoma (TC), could be useful for the treatment of immunocompromised patients with TC.Lenvatinib and sorafenib, among other MKIs, have become the standard of care for advanced TC based on their efficacy data and despite their adverse effects.Currently, published data on MKIs in immunosuppressed patients are scarce.Secondary malignancies can arise in immunosuppressed patients who have undergone solid organ transplantation, human immunodeficiency virus-infected patients, and hematopoietic stem cell transplant recipients. This review will explore different immunosuppression settings, the risk of secondary malignancies in immunosuppressed patients, and the special characteristics of this population. Some considerations regarding anticancer treatment in immunosuppressed patients with advanced malignancies are reviewed. K E Y W O R D Simmunosuppressed patients, multikinase inhibitors, systemic treatment, thyroid carcinoma How to cite this article: Basté Rotllan N. Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.

Association Between the XRCC1, GSTM1, and GSTT1 Polymorphisms in Model of Thyroid Cancer: A Meta-Analysis

“…Thyroid cancer (TC) is the most prevalent malignant tumor within the endocrine system, accounting for approximately 95 % of all malignancies in this system [1]. It can be categorized into different pathological types, including papillary thyroid carcinoma (PTC), follicular thyroid carcinoma (FTC), medullary thyroid carcinoma (MTC), and undifferentiated thyroid carcinoma, with PTC being the most common type [2].…”